Back

The role of the crossover of the using the ranolazine and trimetazidine in dynamics of reduced left ventricular function in patients after anterior or lateral myocardial infarction without myocardial

30 April 2017 (08:30 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Chronic heart failure Chronic Ischaemic heart disease HFA Premium Access Heart Failure 2017 - 4th World Congress on Acute Heart Failure

About the speaker

Photo
Doctor Jafar Ramazanov

Central Hospital of Oilworkers, Baku (Azerbaijan)

91 More presentations in this session

Presentation thumbnail
Assistant Professor D. Hashemi (Berlin, DE)
Presentation thumbnail
Doctor B. Narziev (Tashkent, UZ)
Presentation thumbnail
Presentation thumbnail
Doctor D. Nascimento Matos (Carnaxide, PT)
Abstract
Presentation thumbnail
Doctor F. Ricupati (Palermo, IT)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Chronic heart failure

The Event

Event poster

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

30 April 2017 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Use of trimetazidine in myocardial damage by Covid 19 and LVEF recovery.
20 May 2023
thumbnail
Congress Presentation
Introduction
31 August 2025
thumbnail
Congress Presentation
Impact of rehabilitation on QT dispersion and double product in patients after myocardial infarction and reduced left ventricular ejection fraction - whether the age has an effect on benefit
20 May 2025
thumbnail
Congress Presentation
Pirfenidone added to standard therapy for myocardial infarction further reduces left ventricular fibrosis: a preclinical study
21 May 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources